Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease
Sponsor: Gilead Sciences
Terminated
This trial was terminated. No reason was provided.
This PHASE2 trial investigates Crohn's Disease and is currently terminated or withdrawn. Gilead Sciences leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Apr 2019 — May 2019 [monthly]
Terminated PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Terminated PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Nov 2017 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .